RCT | Panitumumab vs. Bevacizumab added to 1st-line chemo in RAS wild-type left-sided metastatic colorectal cancer

Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial – JAMA (free for a limited period)

Editorial: Anti-EGFR Therapy for Left-Sided RAS Wild-type Colorectal Cancer—PARADIGM Shift – JAMA Oncology (free for a limited period)

Commentary on Twitter

Among patients with RAS wild-type metastatic colorectal cancer, adding panitumumab, vs bevacizumab, to standard first-line chemotherapy significantly improved overall survival in patients with left-sided tumors and in the overall population. https://t.co/Hjh9f3fN1z #AACR23 pic.twitter.com/uZxQUkfNbB

— JAMA (@JAMA_current) April 18, 2023